To include your compound in the COVID-19 Resource Center, submit it here.

Bydureon exenatide once weekly regulatory update

FDA accepted an NDA resubmission from Amylin for Type II diabetes candidate

Read the full 124 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE